<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00722527</url>
  </required_header>
  <id_info>
    <org_study_id>17665</org_study_id>
    <secondary_id>5R01HL050077-13</secondary_id>
    <nct_id>NCT00722527</nct_id>
  </id_info>
  <brief_title>Molecular Biology of Polycythemia and Thrombocytosis</brief_title>
  <official_title>Molecular Biology of Polycythemia and Thrombocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our study is designed to characterize the clinical picture and genetic pattern of
      Polycythemia and Thrombocytosis. The purpose of this project is to find a gene and its
      mutation that causes these disorders. When this is accomplished, new therapies to control and
      eventually cure the disorder can be designed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our hypothesis is that genes and their mutation are causative of certain types of
      polycythemia and thrombocytosis. These will be sought for by genetic and cell biology means.
      The purpose of the study is to identify the molecular defect of these disorders.

      5-7 teaspoons of peripheral blood will be drawn on all study subjects. After DNA is obtained,
      linkage analysis and/or mutation analysis will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identify the molecular defect of Polycythemic and Thrombocythemic disorders</measure>
    <time_frame>Weekly</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Polycythemia</condition>
  <condition>Thrombocytosis</condition>
  <arm_group>
    <arm_group_label>Affected Population</arm_group_label>
    <description>Subjects with an elevated hemoglobin concentration or an elevated platelet count</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who have polycythemia and thrombocytosis will be included in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with an elevated hemoglobin concentration (&gt;18 in males and &gt;16 in females)

          2. Subjects with an elevated platelet count (&gt;450,000)

        Exclusion Criteria:

          1. Subjects who have a known acquired cause of polycythemia and thrombocytosis

          2. Subjects with heart disease, left to right heart shunt or severe pulmonary disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josef T. Prchal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Josef T Prchal, MD</last_name>
    <phone>801-581-4220</phone>
    <email>josef.prchal@hsc.utah.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kim Hickman, BS</last_name>
    <phone>801-581-3707</phone>
    <email>kimberly.hickman@hsc.utah.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josef T Prchal, MD</last_name>
      <phone>801-581-4220</phone>
      <email>josef.prchal@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kim Hickman, BS</last_name>
      <phone>801-581-3707</phone>
      <email>kimberly.hickman@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Josef T Prchal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neeraj Agarwal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dong Yoon, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tatum Simonson, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Percy MJ, Sanchez M, Swierczek S, McMullin MF, Mojica-Henshaw MP, Muckenthaler MU, Prchal JT, Hentze MW. Is congenital secondary erythrocytosis/polycythemia caused by activating mutations within the HIF-2 alpha iron-responsive element? Blood. 2007 Oct 1;110(7):2776-7.</citation>
    <PMID>17881647</PMID>
  </reference>
  <reference>
    <citation>Skoda R, Prchal JT. Lessons from familial myeloproliferative disorders. Semin Hematol. 2005 Oct;42(4):266-73. Review.</citation>
    <PMID>16210040</PMID>
  </reference>
  <reference>
    <citation>Gregg XT, Prchal JT. Recent advances in the molecular biology of congenital polycythemias and polycythemia vera. Curr Hematol Rep. 2005 May;4(3):238-42. Review.</citation>
    <PMID>15865879</PMID>
  </reference>
  <reference>
    <citation>Bento MC, Chang KT, Guan Y, Liu E, Caldas G, Gatti RA, Prchal JT. Congenital polycythemia with homozygous and heterozygous mutations of von Hippel-Lindau gene: five new Caucasian patients. Haematologica. 2005 Jan;90(1):128-9.</citation>
    <PMID>15642680</PMID>
  </reference>
  <reference>
    <citation>Jedlickova K, Stockton DW, Prchal JT. Possible primary familial and congenital polycythemia locus at 7q22.1-7q22.2. Blood Cells Mol Dis. 2003 Nov-Dec;31(3):327-31.</citation>
    <PMID>14636647</PMID>
  </reference>
  <results_reference>
    <citation>Prchal JT, Gordeuk VR. The HIF2A gene in familial erythrocytosis. N Engl J Med. 2008 May 1;358(18):1966; author reply 1966-7.</citation>
    <PMID>18456917</PMID>
  </results_reference>
  <results_reference>
    <citation>Agarwal N, Mojica-Henshaw MP, Simmons ED, Hussey D, Ou CN, Prchal JT. Familial polycythemia caused by a novel mutation in the beta globin gene: essential role of P50 in evaluation of familial polycythemia. Int J Med Sci. 2007 Oct 4;4(4):232-6.</citation>
    <PMID>17952198</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2008</study_first_submitted>
  <study_first_submitted_qc>July 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2008</study_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Familial and Congenital Polycythemia</keyword>
  <keyword>Polycythemia</keyword>
  <keyword>Molecular Biology</keyword>
  <keyword>Genetics</keyword>
  <keyword>Erythropoiesis</keyword>
  <keyword>EPOR mutation</keyword>
  <keyword>Thrombocytosis</keyword>
  <keyword>Hypoxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

